Carolina Bernabe Ramirez, MD
Hematology & Oncology · Bronx, NYNPI 1538501838
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,253 of the $1,452 with a category attached, or 86.2%. 19 manufacturers reported payments, led by AstraZeneca at 24.9% of the total. Reporting peaked in 2022 at $777 and has fallen 98.0% since, to $15 in 2025. That places this record below the midpoint for hematology & oncology clinicians in NY, where the typical reported total is $1,337.
Across 40 payments — averaging $36.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$362
- Seagen Inc.$231
- Pfizer$174
- Jazz Pharmaceuticals Inc.$147
- Novartis$106
- Rigel Pharmaceuticals, Inc.$71
- plus $362 from 13 others
Across 63 payments — averaging $2029.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$128K
What the payments were for
- Food & beverage$1,25386%
- Education$20014%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 6 | $362 |
| Seagen Inc. | 4 | $231 |
| Pfizer | 5 | $174 |
| Jazz Pharmaceuticals Inc. | 1 | $147 |
| Novartis | 6 | $106 |
| Rigel Pharmaceuticals, Inc. | 3 | $71 |
| Bristol Myers Squibb | 2 | $55 |
| Genentech USA, Inc. | 1 | $46 |
| Johnson & Johnson | 2 | $43 |
| Regeneron Healthcare Solutions, Inc. | 1 | $35 |
| Deciphera Pharmaceuticals Inc. | 1 | $27 |
| Ardelyx, Inc. | 1 | $22 |
| Global Blood Therapeutics, Inc. | 1 | $22 |
| Taiho Oncology, Inc. | 1 | $21 |
| Foundation Medicine, Inc. | 1 | $21 |
| AbbVie | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Sanofi | 1 | $15 |
| Stemline Therapeutics Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,452 in reported general payments places this provider in the 50th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 21 | $79,099 |
| Clobetasol Propionate | 12 | $1,309 |
| Ondansetron OdtOndansetron | 60 | $647 |
| Clindamycin Phosphate | 11 | $636 |
| LoperamideLoperamide Hcl | 23 | $351 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 35 | $342 |
| Ondansetron Hcl | 43 | $301 |
| Gabapentin | 41 | $267 |
| Prochlorperazine Maleate | 13 | $194 |
| Mirtazapine | 29 | $191 |
| Famotidine | 15 | $111 |
| Duloxetine Hcl | 12 | $78 |
| Tramadol Hcl | 15 | $45 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Bronx
- Tauseef AhmedBronx$171K
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
- Joshua SabariNew York$761K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.